Medtronic raises annual profit forecast on lower tariff impact

Medtronic (MDT.N) has raised its fiscal 2026 adjusted profit forecast to $5.60-$5.66 per share, up from $5.50-$5.60, citing a significantly reduced expected impact from proposed U.S. tariffs. The medical-device maker now anticipates a tariff impact of approximately $185 million, notably lower than its previous estimate of $200 million-$350 million, reflecting improved clarity on trade policy effects and potentially bolstering investor confidence in the sector's resilience amid sustained demand for non-urgent surgeries.

Analysis

Medtronic (MDT) has issued a positive revision to its fiscal 2026 profit forecast, signaling enhanced confidence in its financial outlook. The company raised its adjusted earnings per share guidance to a range of $5.60 to $5.66, up from the previous forecast of $5.50 to $5.60. This upward adjustment is directly attributed to a significant de-risking of a key geopolitical headwind; the anticipated impact from proposed U.S. tariffs has been reduced to approximately $185 million, a notable improvement from the prior estimate of $200 million to $350 million. This revision occurs within a favorable industry context, where medical-device makers are experiencing sustained demand from non-urgent surgeries, particularly among the aging U.S. population. The combination of reduced external cost pressures and strong underlying market demand points to a more resilient earnings profile for the company.

Key Decisions for Investors

• The upward revision to the FY2026 earnings guidance, coupled with a significant reduction in estimated tariff impact, strengthens the bullish case for Medtronic by improving its earnings visibility and fundamental outlook.
• Investors should recognize that the clarification on tariffs removes a significant overhang of uncertainty, which could warrant a re-evaluation of the company's risk profile and potentially support a higher valuation multiple.
• While the tariff news is a company-specific positive, the sustained demand for non-urgent surgeries remains a critical industry tailwind; continued monitoring of this trend is crucial for validating the long-term growth thesis.